Is Sanjivani Parenteral the Best Stock in Its Sector? A Look at the Numbers
- October 22, 2026
- Posted by: Neeraj Pandey
- Category: Market
Sanjivani Parenteral CMP Rs 163 (22 Oct 2026). Market cap Rs 200 Cr. ROE 13.87%. P/E 26.87x versus Industry P/E 35.97x.
Quick Answer
Sanjivani Parenteral is one of the names investors compare when screening the Parenteral Pharmaceuticals sector. Whether it is the best stock in its sector depends on whether an investor prioritises return ratios, valuation or balance sheet strength. This article sets it against two named peers and the sector benchmark so you can judge for yourself.
Is Sanjivani Parenteral the best stock in its sector? The stock trades on the BSE at Rs 163 as of 22 October 2026, within its 52-week range of Rs 126.00 to Rs 244.00. The sections below cover the business, the key ratios, a peer comparison and a closer look at valuation.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Sanjivani Parenteral
Sanjivani Parenteral Ltd is a research based and export oriented pharmaceutical company, and company information says it was incorporated in 1994. Company information describes a WHO-GMP, DIGEMID and DDA certified company specialising in parenteral and oral solid formulations, with therapeutic areas that include CNS, CVS, antibiotics, urology, anesthetics, gastro enterology, anti-diabetics, anti-fungals, anti-depressants, anti-allergics, muscle relaxants and vitamin supplements. At a market capitalisation of Rs 200 Cr, it is tracked as part of the Parenteral Pharmaceuticals sector on Univest.
Is Sanjivani Parenteral the Best Stock in Its Sector?
Sanjivani Parenteral makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, backed by its return on equity. Sanjivani Parenteral’s 26.87x P/E is below the 35.97x Industry P/E, Ajanta Pharma at 36.31x and Marksans Pharma at 27.32x, while its 13.87% ROE is lower than Ajanta Pharma at 23.33%, though higher than Marksans Pharma at 13.82%, and its debt to equity ratio of 0.30 is above Ajanta Pharma at 0.06 and Marksans Pharma at 0.11.
| Metric | Sanjivani Parenteral |
|---|---|
| CMP (BSE) | Rs 163.10 |
| 52-Week High / Low | Rs 244.00 / Rs 126.00 |
| Market Cap | Rs 200 Cr |
| P/E (TTM) vs Industry P/E | 26.87x vs 35.97x |
| P/B | 4.15 |
| ROE | 13.87% |
| EPS (TTM) | Rs 6.07 |
| Dividend Yield | 0.00% |
| Debt to Equity | 0.30 |
Compare Sanjivani Parenteral Against Other Parenteral Pharmaceuticals Sector Stocks
How Sanjivani Parenteral Compares Against Its Parenteral Pharmaceuticals Sector Peers
The table below sets Sanjivani Parenteral against 2 other Parenteral Pharmaceuticals sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Sanjivani Parenteral | 200 | 26.87 | 13.87% | 0.30 |
| Ajanta Pharma | 41,211 | 36.31 | 23.33% | 0.06 |
| Marksans Pharma | 14,236 | 27.32 | 13.82% | 0.11 |
| Peer average (2 companies) | – | 31.82 | 18.57% | 0.08 |
Measured against the peer averages, Sanjivani Parenteral’s P/E is 16 percent below the 31.82x average, and its ROE is 4.71 percentage points below the 18.57% average. An average of just two companies is a rough guide, so treat the gap as a pointer for further research and not as a verdict.
What Makes Sanjivani Parenteral Worth Watching in Parenteral Pharmaceuticals
- Scale: At Rs 200 Cr, its market capitalisation is smaller than Ajanta Pharma (Rs 41,211 Cr) and Marksans Pharma (Rs 14,236 Cr), which is a useful reminder that the peers differ in size as well as in valuation.
- Sector drivers: Export orders for injectables and tablets, regulatory approvals in overseas markets and the mix of products sold drive revenue and margins.
- Key risk: Pharmaceutical exporters depend on regulatory clearances and on tenders and distributors in overseas markets, so orders can be lumpy. Raw material costs and currency moves can also affect margins.
Sanjivani Parenteral Valuation: Is It Justified?
At a P/B ratio of 4.15, the market pays about Rs 4.15 for every rupee of book value, and the EPS (TTM) of Rs 6.07 is the earnings base behind the P/E. The stock trades about 33 percent below its 52-week high and about 29 percent above its 52-week low. The company does not currently show a dividend yield, so returns for shareholders depend mainly on the share price. As with any single stock, investors should weigh these figures against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Sanjivani Parenteral and other Parenteral Pharmaceuticals sector stocks.
How to Track Sanjivani Parenteral Before You Invest
Before deciding whether Sanjivani Parenteral deserves its label as the best stock in its sector for your own portfolio, compare it directly against Parenteral Pharmaceuticals sector peers using the steps below.
- Open the Univest Screener and search for Sanjivani Parenteral to view live price, valuation ratios, and peer comparisons within the Parenteral Pharmaceuticals sector.
- Compare its P/E, P/B, and ROE against other Parenteral Pharmaceuticals sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Sanjivani Parenteral gives investors a clear set of numbers to work with, from returns and valuation to leverage and peer standing. Whether it earns the label of best stock in Parenteral Pharmaceuticals depends on how much weight you give each of them and on how the business executes from here. Because the stock trades below its sector benchmark, the open question is whether earnings growth will close that gap or whether the discount is deserved. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Sanjivani Parenteral the best stock in its sector?
Ans. There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Sanjivani Parenteral has a 13.87% ROE and trades at 26.87x P/E against a 35.97x Industry P/E. Against the 2 peers compared in this article, its ROE is below the 18.57% peer average and its P/E is below the 31.82x peer average. Its debt to equity ratio of 0.30 is above the 0.08 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.
What is the current share price of Sanjivani Parenteral?
Ans. Sanjivani Parenteral was trading at Rs 163.10 on the BSE as of 22 October 2026, and its 52-week range runs from Rs 126.00 to Rs 244.00. That leaves the share price 33 percent short of the 52-week high and 29 percent clear of the 52-week low. Its market capitalisation is Rs 200 Cr and its EPS (TTM) is Rs 6.07, which is the earnings figure behind the 26.87x P/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.
What sector does Sanjivani Parenteral belong to?
Ans. Sanjivani Parenteral is classified under the Parenteral Pharmaceuticals sector on Univest, and that group of listed companies is the reference point for the 35.97x Industry P/E used in this article. The 2 named peers compared here are Ajanta Pharma and Marksans Pharma, chosen as comparable listed names so that the P/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Parenteral Pharmaceuticals sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.
How does Sanjivani Parenteral compare to its sector peers on P/E?
Ans. Sanjivani Parenteral’s P/E of 26.87x is below the 31.82x average of the 2 named peers, with Ajanta Pharma at 36.31x and Marksans Pharma at 27.32x. It also sits below the 35.97x Industry P/E, which is the benchmark for the wider Parenteral Pharmaceuticals sector. A P/E that is below a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P/B ratio of 4.15 gives one more view of how the market values its book value.
What is Sanjivani Parenteral’s return on equity?
Ans. Sanjivani Parenteral reported a return on equity of 13.87%, which is below the 18.57% average of its named peers, with Ajanta Pharma at 23.33% and Marksans Pharma at 13.82%. ROE shows how much profit a company generates on every rupee of shareholders’ equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.30 against a peer average of 0.08. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.
Should I invest in Sanjivani Parenteral based on its sector position?
Ans. Sector position is only one input into an investment decision. Sanjivani Parenteral has a 13.87% ROE and a 26.87x P/E, which make it worth researching further, and its dividend yield is 0.00%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.
